These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25132024)

  • 21. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
    J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
    Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
    J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
    Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
    Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
    Carter HE; Zannino D; John Simes R; Schofield DJ; Howard K; Zalcberg JR; Price TJ; Tebbutt NC
    Eur J Cancer; 2014 Feb; 50(3):535-43. PubMed ID: 24215848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
    Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
    Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
    J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
    Larsen FO; Boisen MK; Fromm AL; Jensen BV
    Acta Oncol; 2012 Feb; 51(2):231-3. PubMed ID: 21936753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
    Twelves C
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):23-6. PubMed ID: 12520636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
    Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ
    J Clin Oncol; 2010 Jul; 28(19):3191-8. PubMed ID: 20516443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
    Moriwaki T; Gosho M; Sugaya A; Yamada T; Yamamoto Y; Hyodo I
    Cancer Res Treat; 2021 Jul; 53(3):703-713. PubMed ID: 33285056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis.
    Stein A; Schwenke C; Folprecht G; Arnold D
    Clin Colorectal Cancer; 2016 Jun; 15(2):e29-39. PubMed ID: 26781523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal duration of systemic treatment in metastatic colorectal cancer.
    Simkens LH; Koopman M; Punt CJ
    Curr Opin Oncol; 2014 Jul; 26(4):448-53. PubMed ID: 24840523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance therapy for colorectal cancer: which regimen and which patients?
    Mikhail S; Bekaii-Saab T
    Drugs; 2015 Nov; 75(16):1833-42. PubMed ID: 26377935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.
    Aprile G; Giuliani F; Lutrino SE; Fontanella C; Bonotto M; Rihawi K; Fasola G
    Clin Colorectal Cancer; 2016 Mar; 15(1):7-15. PubMed ID: 26421728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of maintenance therapy and complete discontinuation for therapeutic management of non-resectable metastatic colorectal cancer].
    Senellart H; Hiret S; Guerin-Meyer V; Bennouna J
    Bull Cancer; 2014 Jun; 101(6):619-25. PubMed ID: 24977450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials.
    Giuliani J; Bonetti A
    Clin Colorectal Cancer; 2016 Dec; 15(4):277-284. PubMed ID: 27521066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy Maintenance.
    Kasi PM; Grothey A
    Cancer J; 2016; 22(3):199-204. PubMed ID: 27341599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.